» Authors » Michel Lecendreux

Michel Lecendreux

Explore the profile of Michel Lecendreux including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 100
Citations 3024
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Triller A, Pizza F, Lecendreux M, Lieberich L, Rezaei R, Pech de Laclause A, et al.
Sleep Med . 2023 Feb; 103:62-68. PMID: 36758348
Background: First symptoms of narcolepsy mostly present during childhood. Pharmacological management options in children are limited, also due to approval status. Pitolisant is an inverse histamine 3 receptor agonist and...
12.
Konofal E, Lecendreux M, Bizot J, Lormier A, Figadere B
Curr Med Chem . 2023 Jan; 31(9):1069-1081. PMID: 36683369
Background: NLS-3 or (R, R) enantiomer of phacetoperane (levophacetoperane) is the reverse ester of methylphenidate, a well-documented psychostimulant marketed for the treatment of attention-deficit/hyperactivity disorder (ADHD) since the end of...
13.
Gosling C, Cortese S, Konofal E, Lecendreux M, Faraone S
J Am Acad Child Adolesc Psychiatry . 2022 Jun; 62(2):244-252. PMID: 35724815
Objective: Symptoms of attention-deficit/hyperactivity disorder (ADHD) and sleep disturbances frequently co-occur, and can result in significant functional impairments that worsen quality of life. Despite a growing number of studies focusing...
14.
Pech de Laclause A, Konofal E, Bokov P, Delclaux C, Lecendreux M
J Clin Sleep Med . 2022 Jun; 18(9):2247-2252. PMID: 35698456
Study Objectives: The goal of the current study was to explore the effect of a 2-month quarantine on children and adolescents with narcolepsy and to describe the changes in their...
15.
Lecendreux M, Plazzi G, Dauvilliers Y, Rosen C, Ruoff C, Black J, et al.
J Clin Sleep Med . 2022 Jun; 18(9):2217-2227. PMID: 35689598
Study Objectives: Evaluate long-term efficacy and safety of sodium oxybate (SXB) in children and adolescents (aged 7-16 years) with narcolepsy with cataplexy. Methods: A double-blind randomized withdrawal study was conducted....
16.
Leu-Semenescu S, Maranci J, Lopez R, Drouot X, Dodet P, Gales A, et al.
J Clin Sleep Med . 2022 Jan; 18(5):1355-1364. PMID: 34984974
Study Objectives: To assess the frequency, determinants, and clinical impact of clinical rapid eye movement (REM) and non-REM (NREM) parasomnias in adult patients with narcolepsy type 1 (NT1), narcolepsy type...
17.
Pech de Laclause A, Getin C, Konofal E, Cortese S, Lecendreux M
Child Adolesc Ment Health . 2022 Jan; 27(3):312-317. PMID: 34983079
Objective: Our objective is to explore the change in the severity of ADHD, ODD and anxiety during a two-month lockdown among children in France and the moderating role of behavioural...
18.
Bassetti C, Kallweit U, Vignatelli L, Plazzi G, Lecendreux M, Baldin E, et al.
Eur J Neurol . 2021 Jun; 28(9):2815-2830. PMID: 34173695
Background And Aim: Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment. This paper aims to provide evidence-based guidelines for the management of narcolepsy...
19.
Bassetti C, Kallweit U, Vignatelli L, Plazzi G, Lecendreux M, Baldin E, et al.
J Sleep Res . 2021 Jun; 30(6):e13387. PMID: 34173288
Background And Purpose: Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment. This paper aims to provide evidence-based guidelines for the management of narcolepsy...
20.
Barateau L, Lecendreux M, Chenini S, Rassu A, Lopez R, Pesenti C, et al.
Neurology . 2021 May; 97(5):e476-e488. PMID: 34031200
Objective: We validated the Narcolepsy Severity Scale (NSS) in adults with narcolepsy type 1 (NT1) to quantify the severity, frequency, and consequences of the 5 key narcolepsy symptoms over the...